| Original language | English (US) |
|---|---|
| Pages (from-to) | 1361-1365 |
| Number of pages | 5 |
| Journal | Gastroenterology |
| Volume | 161 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2021 |
Bibliographical note
Funding Information:Conflicts of interest The authors have made the following disclosures: David Rubin reports grant support from Takeda; and has served as a consultant for Abbvie, Altrubio, Allergan Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. He is on the Board of Trustees for the Crohn's & Colitis Foundation. Anjana Pillai serves on medical advisory board for Exelixis, Eisai Inc and Genentech, on the safety review committee for Replimune and is on the Speaker's Bureau for Simply Speaking Hepatitis (CME). The other authors report no conflicts.
Funding Information:
Conflicts of interest The authors have made the following disclosures: David Rubin reports grant support from Takeda; and has served as a consultant for Abbvie, Altrubio, Allergan Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. He is on the Board of Trustees for the Crohn’s & Colitis Foundation. Anjana Pillai serves on medical advisory board for Exelixis, Eisai Inc and Genentech, on the safety review committee for Replimune and is on the Speaker’s Bureau for Simply Speaking Hepatitis (CME). The other authors report no conflicts.